Rectal Gonorrhea Test in Kathmandu — Extragenital NAAT Screening Site-specific testing for often-asymptomatic rectal infection

Rectal Gonorrhea: The Hidden Infection

Rectal gonorrhoea — infection of the rectum with Neisseria gonorrhoeae — is an extragenital infection that occurs primarily through receptive anal sex. What makes rectal gonorrhoea clinically significant is that it is frequently asymptomatic — studies suggest the majority of rectal infections cause no noticeable symptoms. This means infected individuals may unknowingly transmit the infection to partners.

The importance of rectal testing extends beyond individual health. Untreated rectal gonorrhoea can serve as a reservoir for ongoing transmission, facilitate HIV transmission (rectal mucosa is particularly susceptible to HIV acquisition), and cause local complications including proctitis, rectal discharge, pain, and bleeding. For men who have sex with men and others who engage in receptive anal sex, rectal testing is essential for complete STI screening.

Standard genital testing — urine or urethral swabs — does not detect rectal infection. Site-specific NAAT testing from a rectal swab is required. Guidelines recommend testing all exposed sites: genital, rectal, and throat. A person may have rectal gonorrhoea without genital infection, making comprehensive site testing critical.

This guide explains rectal gonorrhoea transmission, symptoms, testing methods, treatment, prevention, and how Thamel Clinic provides confidential site-specific testing in Kathmandu.

What Is Rectal Gonorrhea and How Is It Transmitted?

Rectal gonorrhoea is infection of the rectal mucosa with Neisseria gonorrhoeae. Transmission occurs primarily through receptive anal sex — the insertion of a penis into the rectum. Less commonly, it can occur through sharing sex toys, fisting with contaminated hands, or autoinoculation from genital infection.

The bacterium infects the columnar epithelial cells of the rectal mucosa, causing inflammation. Symptoms, when present, include rectal discharge (often mucopurulent), anal itching, pain during defecation, rectal bleeding, and tenesmus (feeling of incomplete evacuation). However, many infections are completely asymptomatic.

Rectal gonorrhoea is particularly important because the rectal mucosa is highly susceptible to HIV transmission. Co-infection with rectal gonorrhoea significantly increases HIV acquisition risk for the receptive partner and transmission risk for the insertive partner. This biological interaction makes rectal STI screening essential for HIV prevention.

• Transmitted primarily through receptive anal sex.
• Infects rectal mucosa causing inflammation (proctitis).
• Symptoms: discharge, pain, bleeding, tenesmus — often absent.
• Rectal mucosa highly susceptible to HIV — co-infection increases risk.
• Can occur with or without genital gonorrhoea.

Testing Methods and Specimen Collection

Rectal gonorrhoea testing uses NAAT (nucleic acid amplification test) — the same molecular method used for genital testing. A swab is inserted approximately 3 to 5 cm into the rectum and rotated to collect cells from the rectal mucosa. The swab is placed in transport medium and sent to the laboratory for analysis.

Self-collection is possible for some patients — clear instructions are provided for proper technique. However, clinician-collected specimens may be preferred for patients uncomfortable with self-collection or for those who want guidance. The procedure is quick and generally well-tolerated.

NAAT offers >95% sensitivity and specificity for rectal gonorrhoea. Results are typically available within 24 to 48 hours. Site-specific testing is essential — a urine test or genital swab will NOT detect rectal infection. Patients should inform the clinician of all sexual practices to ensure appropriate site testing.

• NAAT is gold standard — >95% sensitivity/specificity.
• Swab inserted 3–5 cm into rectum, rotated for mucosal cells.
• Self-collection possible with instructions; clinician collection available.
• Results within 24–48 hours.
• Rectal testing separate from genital/urine — different sites required.

Symptoms, Who Should Test, and Screening Frequency

Rectal gonorrhoea symptoms, when present, include anal discharge (often mucopurulent or bloody), anal itching, pain during bowel movements, rectal bleeding, tenesmus, and rectal pain. Proctitis — inflammation of the rectal lining — may cause more severe symptoms including fever, severe pain, and systemic illness.

Most rectal infections are asymptomatic — studies suggest 85 percent or more cause no noticeable symptoms. This asymptomatic nature means infected individuals may unknowingly transmit to partners. Routine screening is the only reliable detection method for those at risk.

Rectal testing is recommended for all individuals who engage in receptive anal sex, regardless of whether they use condoms. MSM should screen every 3 to 6 months for rectal and other site-specific STIs. Partners of people diagnosed with rectal gonorrhoea should be tested. Those with symptoms suggestive of proctitis should be tested promptly.

• Symptoms: discharge, itching, pain, bleeding, tenesmus — often absent.
• 85%+ of rectal infections asymptomatic — screening essential.
• Test all who engage in receptive anal sex, regardless of condom use.
• MSM: screen every 3–6 months for rectal and site-specific STIs.
• Partners of diagnosed cases should be tested.

Treatment, Partner Management, and Prevention

Rectal gonorrhoea is treated with ceftriaxone — the same first-line therapy as genital infection. A single intramuscular injection of ceftriaxone 500 mg (or 1 g for pharyngeal or higher-weight patients) is curative for uncomplicated infection. Treatment must be completed as prescribed, and sexual activity avoided until treatment is finished.

Partner notification is essential — sexual partners from the past 60 days should be tested and treated. For MSM with multiple partners, this may involve several contacts. Thamel Clinic provides confidential support for partner notification, including anonymous notification options and coordinated partner testing.

Prevention strategies include consistent condom use for anal sex, regular screening every 3 to 6 months for MSM, mutual testing with new partners, and HIV prevention strategies including PrEP where indicated. Rectal gonorrhoea treatment does not provide immunity — reinfection is possible with continued risk behaviour.

• Treatment: ceftriaxone 500 mg IM single dose (1 g if indicated).
• Partners from past 60 days need testing and treatment.
• Avoid sexual activity until treatment complete.
• Prevention: condoms, regular screening, partner testing.
• HIV prevention: PrEP consideration for ongoing risk.

Rectal Gonorrhea Testing Services and Pricing

Prices are indicative; confirm current rates when booking.

Related Services & Guides